The Experts below are selected from a list of 228 Experts worldwide ranked by ideXlab platform

K F Michaelsen - One of the best experts on this subject based on the ideXlab platform.

  • Dose–response Study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults
    European Journal of Clinical Nutrition, 2006
    Co-Authors: C N Larsen, S Nielsen, P Kæstel, E Brockmann, M Bennedsen, H R Christensen, D C Eskesen, B L Jacobsen, K F Michaelsen
    Abstract:

    Objective: This Study was performed to investigate the dose–response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 10^10 CFU/day probiotic and placebo group. Design: The Study was designed as a randomized, placebo-controlled, double-blinded, parallel dose–response Study. Subjects: Healthy young adults (18–40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 (46 women, 25 men, mean age 25.6 years (range 18–40 years)) completed the Study. Intervention: The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 10^8, 10^9, 10^10 or 10^11 CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention. Results: The fecal recovery of BB-12 increased significantly ( P

  • dose response Study of probiotic bacteria bifidobacterium animalis subsp lactis bb 12 and lactobacillus paracasei subsp paracasei crl 341 in healthy young adults
    European Journal of Clinical Nutrition, 2006
    Co-Authors: C N Larsen, P Kæstel, E Brockmann, M Bennedsen, H R Christensen, D C Eskesen, B L Jacobsen, Susanne Dorthe Nielsen, K F Michaelsen
    Abstract:

    This Study was performed to investigate the dose–response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 1010 CFU/day probiotic and placebo group. The Study was designed as a randomized, placebo-controlled, double-blinded, parallel dose–response Study. Healthy young adults (18–40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 (46 women, 25 men, mean age 25.6 years (range 18–40 years)) completed the Study. The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 108, 109, 1010 or 1011 CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention. The fecal recovery of BB-12 increased significantly (P<0.001) with increasing dose. In the group receiving 1011 CFU/day BB-12 was recovered from 13 out of 15 volunteers. CRL-431 was not recovered in any of the fecal samples. Supplementation with probiotics did not change the fecal bacterial composition. A significant linear increase in fecal consistency (looser stool) with increasing probiotic dose (P=0.018) was observed. No overall dose–response effect was found on the blood lipids. High doses of probiotics were well tolerated. A dose-related recovery of BB-12 from feces was observed. The Study was sponsored by Chr. Hansen A/S, Hoersholm, Denmark.

Michael Chopp - One of the best experts on this subject based on the ideXlab platform.

  • a dose response Study of thymosin β4 for the treatment of acute stroke
    Journal of the Neurological Sciences, 2014
    Co-Authors: Daniel C Morris, Yisheng Cui, Wing Lee Cheung, Li Zhang, Zhenggang Zhang, Michael Chopp
    Abstract:

    Abstract Background Thymosin β4 (Tβ4) is a 5 K actin binding peptide. Tβ4 improves neurological outcome in a rat model of embolic stroke and research is now focused on optimizing its dose for clinical trials. The purpose of this Study was to perform a dose–response Study of Tβ4 to determine the optimal dose of neurological improvement in a rat model of embolic stroke. Methods Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo). Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg. Tβ4 was administered intraperitoneally 24 h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion. Neurological tests were performed after MCAo and before treatment and up to 8 weeks after treatment. The rats were sacrificed 56 days after MCAo and lesion volumes measured. Generalized estimating equation was used to compare the treatment effect on long term functional recovery at day 56. A quartic regression model was used for an optimal dose determination. Results Tβ4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values Conclusions This Study shown that Tβ4 significantly improved the long term neurological functional recovery at day 56 after MCAo with an optimal dose of 3.75 mg/kg. These results provide preclinical data for human clinical trials.

  • A dose–response Study of thymosin β4 for the treatment of acute stroke
    Journal of the Neurological Sciences, 2014
    Co-Authors: Daniel C Morris, Yisheng Cui, Li Zhang, Zhenggang Zhang, Lee Cheung, Michael Chopp
    Abstract:

    Abstract Background Thymosin β4 (Tβ4) is a 5 K actin binding peptide. Tβ4 improves neurological outcome in a rat model of embolic stroke and research is now focused on optimizing its dose for clinical trials. The purpose of this Study was to perform a dose–response Study of Tβ4 to determine the optimal dose of neurological improvement in a rat model of embolic stroke. Methods Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo). Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg. Tβ4 was administered intraperitoneally 24 h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion. Neurological tests were performed after MCAo and before treatment and up to 8 weeks after treatment. The rats were sacrificed 56 days after MCAo and lesion volumes measured. Generalized estimating equation was used to compare the treatment effect on long term functional recovery at day 56. A quartic regression model was used for an optimal dose determination. Results Tβ4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values Conclusions This Study shown that Tβ4 significantly improved the long term neurological functional recovery at day 56 after MCAo with an optimal dose of 3.75 mg/kg. These results provide preclinical data for human clinical trials.

  • A Dose-Response Study of thymosin β4 for the treatment of acute stroke.
    Journal of the neurological sciences, 2014
    Co-Authors: Daniel C Morris, Yisheng Cui, Wing Lee Cheung, Li Zhang, Z G Zhang, Michael Chopp
    Abstract:

    Thymosin β4 (Tβ4) is a 5K actin binding peptide. Tβ4 improves neurological outcome in a rat model of embolic stroke and research is now focused on optimizing its dose for clinical trials. The purpose of this Study was to perform a Dose-Response Study of Tβ4 to determine the optimal dose of neurological improvement in a rat model of embolic stroke. Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo). Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg. Tβ4 was administered intraperitoneally 24h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion. Neurological tests were performed after MCAo and before treatment and up to 8 weeks after treatment. The rats were sacrificed 56 days after MCAo and lesion volumes measured. Generalized estimating equation was used to compare the treatment effect on long term functional recovery at day 56. A quartic regression model was used for an optimal dose determination. Tβ4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values <0.05). The higher dose of 18 mg/kg did not show significant improvement. The estimated optimal dose of 3.75 mg/kg would provide optimal neurological improvement. This Study shown that Tβ4 significantly improved the long term neurological functional recovery at day 56 after MCAo with an optimal dose of 3.75 mg/kg. These results provide preclinical data for human clinical trials. Copyright © 2014 Elsevier B.V. All rights reserved.

C N Larsen - One of the best experts on this subject based on the ideXlab platform.

  • Dose–response Study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults
    European Journal of Clinical Nutrition, 2006
    Co-Authors: C N Larsen, S Nielsen, P Kæstel, E Brockmann, M Bennedsen, H R Christensen, D C Eskesen, B L Jacobsen, K F Michaelsen
    Abstract:

    Objective: This Study was performed to investigate the dose–response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 10^10 CFU/day probiotic and placebo group. Design: The Study was designed as a randomized, placebo-controlled, double-blinded, parallel dose–response Study. Subjects: Healthy young adults (18–40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 (46 women, 25 men, mean age 25.6 years (range 18–40 years)) completed the Study. Intervention: The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 10^8, 10^9, 10^10 or 10^11 CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention. Results: The fecal recovery of BB-12 increased significantly ( P

  • dose response Study of probiotic bacteria bifidobacterium animalis subsp lactis bb 12 and lactobacillus paracasei subsp paracasei crl 341 in healthy young adults
    European Journal of Clinical Nutrition, 2006
    Co-Authors: C N Larsen, P Kæstel, E Brockmann, M Bennedsen, H R Christensen, D C Eskesen, B L Jacobsen, Susanne Dorthe Nielsen, K F Michaelsen
    Abstract:

    This Study was performed to investigate the dose–response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 1010 CFU/day probiotic and placebo group. The Study was designed as a randomized, placebo-controlled, double-blinded, parallel dose–response Study. Healthy young adults (18–40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 (46 women, 25 men, mean age 25.6 years (range 18–40 years)) completed the Study. The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 108, 109, 1010 or 1011 CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention. The fecal recovery of BB-12 increased significantly (P<0.001) with increasing dose. In the group receiving 1011 CFU/day BB-12 was recovered from 13 out of 15 volunteers. CRL-431 was not recovered in any of the fecal samples. Supplementation with probiotics did not change the fecal bacterial composition. A significant linear increase in fecal consistency (looser stool) with increasing probiotic dose (P=0.018) was observed. No overall dose–response effect was found on the blood lipids. High doses of probiotics were well tolerated. A dose-related recovery of BB-12 from feces was observed. The Study was sponsored by Chr. Hansen A/S, Hoersholm, Denmark.

Donald G. Stein - One of the best experts on this subject based on the ideXlab platform.

  • Progesterone in transient ischemic stroke: a dose–response Study
    Psychopharmacology, 2014
    Co-Authors: Seema Yousuf, Fahim Atif, Iqbal Sayeed, Huiling Tang, Donald G. Stein
    Abstract:

    Rationale Previous studies demonstrate the neuroprotective effects of progesterone in numerous animal injury models, but a systematic dose–response Study in a transient ischemic stroke model is lacking. Objectives We investigated the effects of progesterone at different doses on post-stroke brain infarction and functional deficits in middle-aged rats. Methods Cerebral ischemia was induced in 13-month-old male Sprague–Dawley rats by right middle cerebral artery occlusion for 2 h followed by reperfusion. Rats received intraperitoneal injections of 8, 16, or 32 mg/kg of progesterone (P8, P16, P32) or vehicle at 2 h post-occlusion followed by subcutaneous injections at 6 h and every 24 h post-injury for 7 days. Functional recovery was evaluated at intervals over 22 days using motor, sensory, and cognitive tests. Infarct size was evaluated at 22 days post-stroke. Results Repeated-measures ANOVA showed significant group effects on grip strength, rotarod, and sensory neglect. All progesterone-treated groups had improved ( p  

  • Progesterone in transient ischemic stroke: a Dose-Response Study.
    Psychopharmacology, 2014
    Co-Authors: Seema Yousuf, Fahim Atif, Iqbal Sayeed, Huiling Tang, Donald G. Stein
    Abstract:

    Rationale Previous studies demonstrate the neuroprotective effects of progesterone in numerous animal injury models, but a systematic dose–response Study in a transient ischemic stroke model is lacking.

P Kæstel - One of the best experts on this subject based on the ideXlab platform.

  • Dose–response Study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults
    European Journal of Clinical Nutrition, 2006
    Co-Authors: C N Larsen, S Nielsen, P Kæstel, E Brockmann, M Bennedsen, H R Christensen, D C Eskesen, B L Jacobsen, K F Michaelsen
    Abstract:

    Objective: This Study was performed to investigate the dose–response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 10^10 CFU/day probiotic and placebo group. Design: The Study was designed as a randomized, placebo-controlled, double-blinded, parallel dose–response Study. Subjects: Healthy young adults (18–40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 (46 women, 25 men, mean age 25.6 years (range 18–40 years)) completed the Study. Intervention: The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 10^8, 10^9, 10^10 or 10^11 CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention. Results: The fecal recovery of BB-12 increased significantly ( P

  • dose response Study of probiotic bacteria bifidobacterium animalis subsp lactis bb 12 and lactobacillus paracasei subsp paracasei crl 341 in healthy young adults
    European Journal of Clinical Nutrition, 2006
    Co-Authors: C N Larsen, P Kæstel, E Brockmann, M Bennedsen, H R Christensen, D C Eskesen, B L Jacobsen, Susanne Dorthe Nielsen, K F Michaelsen
    Abstract:

    This Study was performed to investigate the dose–response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 1010 CFU/day probiotic and placebo group. The Study was designed as a randomized, placebo-controlled, double-blinded, parallel dose–response Study. Healthy young adults (18–40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 (46 women, 25 men, mean age 25.6 years (range 18–40 years)) completed the Study. The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 108, 109, 1010 or 1011 CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention. The fecal recovery of BB-12 increased significantly (P<0.001) with increasing dose. In the group receiving 1011 CFU/day BB-12 was recovered from 13 out of 15 volunteers. CRL-431 was not recovered in any of the fecal samples. Supplementation with probiotics did not change the fecal bacterial composition. A significant linear increase in fecal consistency (looser stool) with increasing probiotic dose (P=0.018) was observed. No overall dose–response effect was found on the blood lipids. High doses of probiotics were well tolerated. A dose-related recovery of BB-12 from feces was observed. The Study was sponsored by Chr. Hansen A/S, Hoersholm, Denmark.